C-Reactive Protein Test (CRP) Market Size, Share Global Analysis Report, 2026-2034

Industry Insights

[228+ Pages Report] According to Facts & Factors, the global C-Reactive Protein test (CRP) market size was estimated at USD 2.55 billion in 2025 and is expected to reach USD 3.95 billion by the end of 2034. The C-Reactive Protein test (CRP) industry is anticipated to grow by a CAGR of 4.9% between 2026 and 2034. The C-Reactive Protein test (CRP) Market is driven by the escalating global prevalence of chronic inflammatory conditions and cardiovascular diseases coupled with the rising adoption of point-of-care testing solutions.

Market Overview

The C-Reactive Protein (CRP) test market encompasses the global industry dedicated to the development, production, and distribution of diagnostic assays used to measure the levels of C-reactive protein in the blood. CRP is an acute-phase reactant synthesized by the liver, serving as a critical biomarker for systemic inflammation caused by infections, autoimmune disorders, and tissue injuries. This market serves a vital role in clinical diagnostics by providing clinicians with a non-specific yet highly sensitive tool to identify underlying inflammatory processes, monitor the progression of chronic diseases, and evaluate the efficacy of therapeutic interventions. As healthcare shifts toward preventive medicine and early intervention, the utility of CRP testing has expanded from acute infection management to long-term risk assessment for conditions such as coronary artery disease and rheumatoid arthritis. The integration of high-sensitivity assays (hs-CRP) has further broadened the market’s scope, allowing for the detection of minute protein fluctuations that indicate low-grade chronic inflammation, thereby positioning these tests as a cornerstone of modern diagnostic protocols.

Key Insights

• As per the analysis shared by our research analyst, the global C-Reactive Protein test (CRP) market is projected to grow annually at a CAGR of around 4.9% over the forecast period (2026-2034).
• In terms of revenue, the market was valued at nearly USD 2.55 billion in 2025 and is set to reach USD 3.95 billion by 2034.
• The market is driven by the increasing incidence of cardiovascular disorders and the growing demand for rapid point-of-care (POC) diagnostic tools that facilitate immediate clinical decision-making.
• Based on the assay type, the Immunoturbidimetric Assay segment dominated the market with a share of approximately 48% in 2025 because of its high throughput, cost-effectiveness, and seamless integration into automated laboratory analyzers.
• Based on the detection range, the High-sensitivity CRP (hs-CRP) segment dominated the market with a share of over 42% in 2025 as it is essential for predicting cardiovascular risk and identifying low-grade inflammation that standard tests might miss.
• Based on the disease area, the Cardiovascular Diseases segment dominated the market with a share of 28% in 2025 due to the high global mortality rate associated with heart conditions and the mandatory use of CRP markers in cardiac risk profiling.
• Based on the end-user, the Diagnostic Laboratories segment dominated the market with a share of 40% in 2025 because these facilities handle massive sample volumes and possess the specialized equipment required for accurate, high-sensitivity protein analysis.
• North America accounted for the largest market share of 34.5% in 2025, dominated by the United States, due to its advanced healthcare infrastructure, high healthcare spending, and proactive screening guidelines for chronic diseases.

Growth Drivers

• Rising Global Burden of Chronic and Inflammatory Diseases

The escalating prevalence of chronic ailments such as rheumatoid arthritis, inflammatory bowel disease (IBD), and cardiovascular diseases is a primary catalyst for market growth. As these conditions require continuous monitoring of inflammatory markers to manage treatment and prevent flare-ups, the demand for regular CRP testing has surged. Aging populations worldwide further contribute to this trend, as the elderly are more susceptible to systemic inflammation and age-related chronic disorders.

Furthermore, the clinical shift toward early disease detection has made CRP testing a staple in routine health screenings. Public health initiatives and medical associations are increasingly recommending inflammatory marker assessments to identify at-risk populations before symptoms become severe. This proactive approach to healthcare ensures a steady volume of test prescriptions, bolstering the revenue of diagnostic kit manufacturers and clinical laboratories alike.

Restraints

• Limited Specificity and Inconclusive Diagnostic Results

A significant restraint for the market is the non-specific nature of C-reactive protein. While a high CRP level confirms the presence of inflammation, it does not pinpoint the exact cause or location of the issue. This limitation means that CRP tests must often be paired with more expensive and complex diagnostic procedures to reach a definitive diagnosis, which can deter healthcare providers from relying solely on CRP as a primary diagnostic tool.

Additionally, various external factors such as obesity, minor injuries, or even certain medications can lead to temporary elevations in CRP levels, resulting in potential false-positive interpretations. These inconclusive results can lead to unnecessary follow-up testing and increased healthcare costs, creating a level of skepticism among clinicians regarding the standalone value of conventional CRP assays in specific diagnostic scenarios.

Opportunities

• Expansion of Point-of-Care (POC) and Home-Based Testing

The development of portable, user-friendly CRP testing platforms presents a massive opportunity for market expansion. Point-of-care testing allows for rapid results within minutes at the bedside, in physician offices, or even in remote clinics, significantly reducing the turnaround time compared to traditional laboratory-based testing. This is particularly beneficial in emergency departments where quick differentiation between bacterial and viral infections is crucial for antibiotic stewardship.

Moreover, the trend toward decentralized healthcare is driving interest in home-based inflammation monitoring kits. As telehealth and personalized medicine gain traction, consumers are seeking ways to track their health markers independently. Companies that can successfully navigate the regulatory hurdles to launch accurate, consumer-grade CRP tests for home use are likely to tap into a significant and rapidly growing market segment.

Challenges

• Stringent Regulatory Requirements and High Equipment Costs

The diagnostic industry faces rigorous regulatory oversight, with organizations like the FDA and EMA requiring extensive clinical validation for new assays. The time-consuming and expensive process of obtaining approvals can delay the market entry of innovative technologies. For smaller diagnostic companies, the financial burden of compliance and the risk of regulatory rejection pose substantial barriers to entry and innovation.

Furthermore, the initial capital investment required for high-throughput automated analyzers and sophisticated high-sensitivity platforms is prohibitive for many small-to-mid-sized clinics and laboratories, especially in emerging economies. This high cost of entry limits the accessibility of advanced CRP testing in developing regions, creating a digital and diagnostic divide that hinders global market penetration.

Report Scope

Market Segmentation

The C-Reactive Protein test (CRP) market is segmented by assay type, detection range, disease area, end-user, and region.

Based on Assay Type Segment, the C-Reactive Protein test (CRP) market is divided into Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay (CLIA), and others. The Immunoturbidimetric Assay is the most dominant subsegment because it offers a perfect balance of speed and precision, allowing large-scale hospitals to process hundreds of samples per hour. The second most dominant subsegment is ELISA, which remains highly relevant due to its exceptional sensitivity and its widespread use in clinical research and specialized diagnostic applications where deep quantification of protein levels is necessary.

Based on Detection Range Segment, the C-Reactive Protein test (CRP) market is divided into High-sensitivity CRP (hs-CRP), Conventional CRP, and cCRP. The High-sensitivity CRP (hs-CRP) subsegment is the most dominant as it can detect inflammation at much lower thresholds, making it indispensable for predicting cardiovascular events in otherwise healthy-looking individuals. The Conventional CRP subsegment is the second most dominant, serving as the standard tool for monitoring acute infections and major inflammatory flare-ups in clinical settings worldwide.

Based on Disease Area Segment, the C-Reactive Protein test (CRP) market is divided into Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Lupus, and others. Cardiovascular Diseases represent the most dominant segment because CRP is a proven independent predictor of heart attacks and strokes, leading to its inclusion in standard cardiac risk panels. Rheumatoid Arthritis is the second most dominant subsegment, as CRP levels are the primary metric used by rheumatologists to measure disease activity and adjust immunosuppressive treatments.

Based on End-user Segment, the C-Reactive Protein test (CRP) market is divided into Hospitals, Clinics, Diagnostic Laboratories, and others. Diagnostic Laboratories are the most dominant end-users because they possess the infrastructure to handle the high volume of tests ordered by primary care physicians and specialists. Hospitals are the second most dominant subsegment, as they utilize CRP testing for acute patient management, post-operative monitoring, and emergency triage to detect sepsis or severe infections quickly.

Recent Developments

• In November 2022, LumiraDx launched its highly sensitive CRP point-of-care test in various markets, aimed at reducing the over-prescription of antibiotics by providing immediate diagnostic clarity in primary care.

• In January 2024, Siemens Healthineers introduced the Atellica CH 900 System, which features an enhanced hs-CRP assay designed to improve the detection of low-grade inflammation in chronic disease patients.
• In 2023, Roche Diagnostics expanded its menu for the Elecsys platform by including an ultrasensitive CRP assay, providing clinicians with improved specificity for long-term cardiac risk assessment.

Regional Analysis

• North America to dominate the global market

North America represents the largest regional market for C-Reactive Protein testing, holding a significant majority of the global share. The United States is the primary contributor to this dominance, driven by a highly developed healthcare system and the presence of major diagnostic companies. The region's market growth is supported by favorable reimbursement policies and a high awareness of preventive healthcare among the population. Furthermore, the high prevalence of obesity and sedentary lifestyles in the U.S. has led to an increased incidence of cardiovascular diseases, making CRP testing a routine part of medical check-ups. The rapid adoption of technologically advanced point-of-care devices also ensures that North America remains at the forefront of the diagnostic industry.

Europe follows as a significant market, with countries like Germany, the UK, and France leading the way. The growth in this region is attributed to the presence of universal healthcare systems that emphasize early diagnosis and the management of chronic inflammatory conditions. Asia Pacific is identified as the fastest-growing region, with China and India emerging as powerhouse markets due to their massive populations, increasing healthcare expenditures, and expanding network of diagnostic laboratories. Latin America and the Middle East & Africa show steady growth, fueled by government initiatives to improve medical infrastructure and the rising middle-class demand for quality diagnostic services.

Competitive Analysis

The global C-Reactive Protein test (CRP) market is dominated by players:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• Thermo Fisher Scientific, Inc.
• Danaher Corporation (Beckman Coulter)
• Quest Diagnostics Incorporated
• Merck KGaA
• Randox Laboratories Ltd.
• Horiba, Ltd.
• LumiraDx
• Getein Biotech, Inc.
• Boditech Med Inc.

The global C-Reactive Protein test (CRP) market is segmented as follows:

By Assay Type

• Immunoturbidimetric Assay
• ELISA (Clinical and Non-clinical)
• Chemiluminescence Immunoassay (CLIA)
• Others

By Detection Range

• High-sensitivity CRP (hs-CRP)
• Conventional CRP
• cCRP (Cardiac-specific CRP)

By Disease Area

• Cardiovascular Diseases
• Cancer
• Rheumatoid Arthritis
• Inflammatory Bowel Disease
• Lupus
• Others

By End-user

• Hospitals
• Clinics
• Diagnostic Laboratories
• Assisted Living Facilities
• Home Care

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America